खून का कैंसर
Leflunomide to Prevent Cytomegalovirus Reactivation in Stem Cell Transplant Patients
कहाँ जाना है
इस trial के लिए 1 hospital भारत में मरीज़ ले रहा है।
रजिस्ट्री समरी (तकनीकी)
Patients undergoing half-matched hematopoietic stem cell transplantation (HSCT) are at high risk of viral reactivation after bone marrow transplantation (BMT). The purpose of this study is to evaluate whether leflunomide can prevent cytomegalovirus (CMV) reactivation in these patients and to assess its safety. The main questions it aims to answer are - 1. Does leflunomide prevent cytomegalovirus (CMV) related organ damage? 2. Does leflunomide prevent a rise in cytomegalovirus (CMV) copy number to more than 2000 copies/ml? 3. Does leflunomide prevent the need to start pre-emptive therapy for …
स्पॉन्सर: टाटा मेमोरियल सेंटर
NCT07709013 ऑन क्लिनिकलट्रायल्स.गव
रजिस्ट्री पर आखिरी अपडेट 16 जुलाई 2026 · हमने 20 अक्टूबर 2026 को पढ़ा